Meditab Specialities is a wholly-owned subsidiary of
Without disclosing the deal measurement, Rubicon Research stated the Satara facility is cGMP compliant and MHRA (UK)-inspected manufacturing website.
The facility permits a robust and numerous pipeline of oral liquids for Rubicon Research, it stated in an announcement.
“The acquisition of an outstanding oral liquid and nasal inhalers manufacturing facility advances our plan to offer a wider portfolio to our customers,” Rubicon Research CEO Parag Sancheti stated.
These capabilities mixed with Rubicon’s analysis and improvement experience strengthens the corporate’s means to supply best-in-class drug merchandise throughout dosage types, he added.